文献速递头颈儿科影像神经MR

视网膜母细胞瘤癌症分期诊断影像:为眼科与肿瘤科医生提供关键见解的指南

Diagnostic Imaging for Retinoblastoma Cancer Staging: Guide for Providing Essential Insights for Ophthalmologists and Oncologists.
PubMed 文献 · Radiographics · 2024-01-01

视网膜母细胞瘤是儿童最常见的眼内恶性肿瘤,由RB1抑癌基因功能缺失或MYCN扩增所致,近半数为遗传性胚系RB1变异且多为双侧。本文讨论MRI及其他诊断影像技术在视网膜母细胞瘤治疗前评估和分期中的作用,并概述现行影像标准及各项技术利弊的证据。

要点

  • MRI是视网膜母细胞瘤治疗前分期评估的重要影像手段。
  • AJCC分期手册已更新,形成多学科管理的通用分期系统。
  • 胚系RB1变异者需关注颅内中线胚胎性肿瘤风险。

核心结论

  • 准确的视网膜母细胞瘤分期对于实现最佳视力、保眼和保命治疗至关重要。

研究设计与样本

  • 本文为综述,讨论MRI及其他诊断影像技术在视网膜母细胞瘤治疗前评估和分期中的作用。

诊断标准与关键数值

  • 采用AJCC癌症分期手册的分期系统进行视网膜母细胞瘤分期。

临床应用与阅片要点

  • 治疗前应利用MRI及其他诊断影像技术进行评估和分期,以指导多学科治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Retinoblastoma is the most common cause of all intraocular pediatric malignancies. It is caused by the loss of RB1 tumor suppressor gene function, although some tumors occur due to MYCN oncogene amplification with normal RB1 genes. Nearly half of all retinoblastomas occur due to a hereditary germline RB1 pathogenic variant, most of which manifest with bilateral tumors. This germline RB1 mutation also predisposes to intracranial midline embryonal tumors. Accurate staging of retinoblastoma is crucial in providing optimal vision-, eye-, and life-saving treatment. The AJCC Cancer Staging Manual has undergone significant changes, resulting in a universally accepted system with a multidisciplinary approach for managing retinoblastoma. The authors discuss the role of MRI and other diagnostic imaging techniques in the pretreatment assessment and staging of retinoblastoma. A thorough overview of the prevailing imaging standards and evidence-based perspectives on the benefits and drawbacks of these techniques is provided. Published under a CC BY 4.0 license. Test Your Knowledge questions for this article are available in the supplemental material.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Pai V, Muthusami P, Ertl-Wagner B, et al. Diagnostic Imaging for Retinoblastoma Cancer Staging: Guide for Providing Essential Insights for Ophthalmologists and Oncologists. Radiographics. 2024. PMID: 38451848. doi:10.1148/rg.230125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。